衛報報告葛蘭素史克公司股價下跌 但沒有提及未測試豬流感刺戳爭議
Guardian Reports on GSK Share Price Slide But Not on Untested Swine Flu Jab Controversy
Wednesday, 06 January 2010 11:59
News - Latest News
The Guardian newspaper has not reported on the controversy that led up to the decision by the French government to cancel 50 million untested swine flu jabs - but it did report on January 5th on the resulting drop in GlaxoSmithKline's share price.
衛報沒有報導有關爭議，它引致法國政府決定取消五千萬劑未經測試的豬流感刺戳-但它卻有報告1月5日的葛蘭素史克公司的股票價格結果下降。
GlaxoSmithKline slips after France cuts back on swine flu vaccine
The FTSE 100 may be on the rise again - up nearly 30 points at the moment - but GlaxoSmithKline is missing out on the rally.
Shares in the pharmaceutical group are down 28p at 1311.5p on concerns about the revenue prospects for its swine flu vaccine. This has been prompted by news yesterday that France has cancelled 50m doses of H1N1 vaccine from Glaxo and other suppliers, around half of the shots it had ordered. Traders said that the initial thought was that two shots per person would be needed, but now one may be sufficient.
The French move followed decisions by Spain, Germany and Switzerland last month to cut deliveries. Analysts are therefore becoming increasingly pessimistic about revenue and earnings prospects for the vaccine.
http://www.guardian.co.uk/business/marketforceslive/2010/jan/05/glaxosmithkline
http://www.theflucase.com/index.php?option=com_content&view=article&id=2479%3Aguardian-reports-on-gsk-share-price-slide-but-not-on-untested-swine-flu-jab-controversy&catid=1%3Alatest-news&Itemid=64&lang=en
沒有留言:
發佈留言